Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.494 EUR | 0.00% |
|
+4.17% | -25.97% |
Jul. 01 | Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine | MT |
Jul. 01 | New semester, new state of mind | ![]() |
PARIS (Reuters) - Shares in biotech firm Valneva dropped as much as 6.9% on Tuesday after the European Union drug regulator said the firm's COVID-19 vaccine was under an EU rolling review but it was still awaiting some additional data.
Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
1st Jan change | Capi. | |
---|---|---|
-25.97% | 529M | |
+22.30% | 47.96B | |
+0.83% | 42.45B | |
+43.91% | 41.47B | |
+27.04% | 31.6B | |
+21.26% | 28.63B | |
-4.47% | 28.03B | |
+52.55% | 14.56B | |
+44.78% | 14.14B | |
+3.05% | 12.58B |